drugset / Trial / NCT02400346
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment
Timeline
- Start
- 2015-03
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexpiprazole | Small molecule | 1 mg | Oral |
| Subject | Brexpiprazole | Small molecule | 2 mg | Oral |
| Subject | Brexpiprazole | Small molecule | 3 mg | Oral |
| Background | Agomelatine | Small molecule | — | — |
| Background | Bupropion | Small molecule | — | — |
| Background | Citalopram | Small molecule | — | — |
| Background | Desvenlafaxine | Other / unclassified | — | — |
| Background | Duloxetine | Small molecule | — | — |
| Background | Fluoxetine | Small molecule | — | — |
| Background | Mirtazapine | Other / unclassified | — | — |
| Background | Paroxetine | Small molecule | — | — |
| Background | Sertraline | Small molecule | — | — |
| Background | Venlafaxine | Small molecule | — | — |
| Background | ecitalopram | Unknown | — | — |